Global Unfractionated Heparin Market Growth 2025-2031
Product Code: 1660271
Industry: Pharma & Healthcare
Published: Jun 25,2025
Pages: 142
Delivery Time: 2-3 business days
Global Unfractionated Heparin Market Growth 2025-2031
Product Code: 1660271
Industry: Pharma & Healthcare
Published: Jun 25,2025
Pages: 142
Delivery Time: 2-3 business days
Select A Format
Single User License
USD3660
Multi Users License
USD5490
Corporate Users License
USD7320
Buy Now
Add To Cart
Or More Options：
PDF Download
Sample Request
Custom Request
Description
The global Unfractionated Heparin market size is predicted to grow from US$ 1059 million in 2025 to US$ 1320 million in 2031; it is expected to grow at a CAGR of 3.7% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Unfractionated Heparin (UFH) is a fast-acting anticoagulant (blood thinner) used to prevent and treat blood clots. It is derived from animal tissues (usually pig intestines or cow lungs) and consists of a mixture of glycosaminoglycan chains of varying lengths.
Although heparin can be synthesized by means of chemical processes, most of the worldwide produced heparin is extracted from animal tissue, porcine intestinal mucosa specifically. The production of heparin is located near the source of raw material. Area’s like China, North America and Europa are the main pork producing areas and these are also the locations of the main heparin producers. More than 65% of the world's heparin APIs are supplied by Chinese companies.
Heparin’s main source, porcine intestinal mucosa, is a by-product of pork slaughtering and is released while cleaning the pork’s casing. Cleaning casings is a specialized process that requires highly skilled staff and state of the art equipment. To avoid degradation of the heparin content and decay, stabilizing agent is added directly after harvesting. The material is stored in bulk tanks awaiting transport to the processing facility. There are also some Bovine-derived APIs on the market, but they are very few, accounting for about 2% to 4% of the global market share.
The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.
LP Information, Inc. (LPI) ' newest research report, the “Unfractionated Heparin Industry Forecast” looks at past sales and reviews total world Unfractionated Heparin sales in 2024, providing a comprehensive analysis by region and market sector of projected Unfractionated Heparin sales for 2025 through 2031. With Unfractionated Heparin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Unfractionated Heparin industry.
This Insight Report provides a comprehensive analysis of the global Unfractionated Heparin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Unfractionated Heparin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Unfractionated Heparin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Unfractionated Heparin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Unfractionated Heparin.
This report presents a comprehensive overview, market shares, and growth opportunities of Unfractionated Heparin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Heparin Sodium
Heparin Calcium
Segmentation by Application:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Myocardial Infarction
Unstable Angina
Atrial Fibrillation-related Clots
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Pfizer
Organon Canada
Leo Pharma
Panpharma
Rotexmedica GmbH
Bharat Serums and Vaccines
Troikaa Pharmaceuticals
Wellona Pharma
B. Braun
Bioiberica
Sagent Pharmaceuticals, Inc
Gland Pharma Limited
Stanex
Mylan
Rewine Pharmaceutical
Jianyou Pharmaceutical
Shenzhen Techdow Pharmaceutical
Changshan Pharma
Dongcheng Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Unfractionated Heparin market?
What factors are driving Unfractionated Heparin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Unfractionated Heparin market opportunities vary by end market size?
How does Unfractionated Heparin break out by Type, by Application?
Table Of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Unfractionated Heparin Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Unfractionated Heparin by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Unfractionated Heparin by Country/Region, 2020, 2024 & 2031
2.2 Unfractionated Heparin Segment by Type
2.2.1 Heparin Sodium
2.2.2 Heparin Calcium
2.3 Unfractionated Heparin Sales by Type
2.3.1 Global Unfractionated Heparin Sales Market Share by Type (2020-2025)
2.3.2 Global Unfractionated Heparin Revenue and Market Share by Type (2020-2025)
2.3.3 Global Unfractionated Heparin Sale Price by Type (2020-2025)
2.4 Unfractionated Heparin Segment by Application
2.4.1 Deep Vein Thrombosis (DVT)
2.4.2 Pulmonary Embolism (PE)
2.4.3 Myocardial Infarction
2.4.4 Unstable Angina
2.4.5 Atrial Fibrillation-related Clots
2.4.6 Other
2.5 Unfractionated Heparin Sales by Application
2.5.1 Global Unfractionated Heparin Sale Market Share by Application (2020-2025)
2.5.2 Global Unfractionated Heparin Revenue and Market Share by Application (2020-2025)
2.5.3 Global Unfractionated Heparin Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Unfractionated Heparin Breakdown Data by Company
3.1.1 Global Unfractionated Heparin Annual Sales by Company (2020-2025)
3.1.2 Global Unfractionated Heparin Sales Market Share by Company (2020-2025)
3.2 Global Unfractionated Heparin Annual Revenue by Company (2020-2025)
3.2.1 Global Unfractionated Heparin Revenue by Company (2020-2025)
3.2.2 Global Unfractionated Heparin Revenue Market Share by Company (2020-2025)
3.3 Global Unfractionated Heparin Sale Price by Company
3.4 Key Manufacturers Unfractionated Heparin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Unfractionated Heparin Product Location Distribution
3.4.2 Players Unfractionated Heparin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Unfractionated Heparin by Geographic Region
4.1 World Historic Unfractionated Heparin Market Size by Geographic Region (2020-2025)
4.1.1 Global Unfractionated Heparin Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Unfractionated Heparin Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Unfractionated Heparin Market Size by Country/Region (2020-2025)
4.2.1 Global Unfractionated Heparin Annual Sales by Country/Region (2020-2025)
4.2.2 Global Unfractionated Heparin Annual Revenue by Country/Region (2020-2025)
4.3 Americas Unfractionated Heparin Sales Growth
4.4 APAC Unfractionated Heparin Sales Growth
4.5 Europe Unfractionated Heparin Sales Growth
4.6 Middle East & Africa Unfractionated Heparin Sales Growth
5 Americas
5.1 Americas Unfractionated Heparin Sales by Country
5.1.1 Americas Unfractionated Heparin Sales by Country (2020-2025)
5.1.2 Americas Unfractionated Heparin Revenue by Country (2020-2025)
5.2 Americas Unfractionated Heparin Sales by Type (2020-2025)
5.3 Americas Unfractionated Heparin Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Unfractionated Heparin Sales by Region
6.1.1 APAC Unfractionated Heparin Sales by Region (2020-2025)
6.1.2 APAC Unfractionated Heparin Revenue by Region (2020-2025)
6.2 APAC Unfractionated Heparin Sales by Type (2020-2025)
6.3 APAC Unfractionated Heparin Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Unfractionated Heparin by Country
7.1.1 Europe Unfractionated Heparin Sales by Country (2020-2025)
7.1.2 Europe Unfractionated Heparin Revenue by Country (2020-2025)
7.2 Europe Unfractionated Heparin Sales by Type (2020-2025)
7.3 Europe Unfractionated Heparin Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Unfractionated Heparin by Country
8.1.1 Middle East & Africa Unfractionated Heparin Sales by Country (2020-2025)
8.1.2 Middle East & Africa Unfractionated Heparin Revenue by Country (2020-2025)
8.2 Middle East & Africa Unfractionated Heparin Sales by Type (2020-2025)
8.3 Middle East & Africa Unfractionated Heparin Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Unfractionated Heparin
10.3 Manufacturing Process Analysis of Unfractionated Heparin
10.4 Industry Chain Structure of Unfractionated Heparin
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Unfractionated Heparin Distributors
11.3 Unfractionated Heparin Customer
12 World Forecast Review for Unfractionated Heparin by Geographic Region
12.1 Global Unfractionated Heparin Market Size Forecast by Region
12.1.1 Global Unfractionated Heparin Forecast by Region (2026-2031)
12.1.2 Global Unfractionated Heparin Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Unfractionated Heparin Forecast by Type (2026-2031)
12.7 Global Unfractionated Heparin Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Unfractionated Heparin Product Portfolios and Specifications
13.1.3 Sanofi Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Unfractionated Heparin Product Portfolios and Specifications
13.2.3 Pfizer Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Organon Canada
13.3.1 Organon Canada Company Information
13.3.2 Organon Canada Unfractionated Heparin Product Portfolios and Specifications
13.3.3 Organon Canada Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Organon Canada Main Business Overview
13.3.5 Organon Canada Latest Developments
13.4 Leo Pharma
13.4.1 Leo Pharma Company Information
13.4.2 Leo Pharma Unfractionated Heparin Product Portfolios and Specifications
13.4.3 Leo Pharma Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Leo Pharma Main Business Overview
13.4.5 Leo Pharma Latest Developments
13.5 Panpharma
13.5.1 Panpharma Company Information
13.5.2 Panpharma Unfractionated Heparin Product Portfolios and Specifications
13.5.3 Panpharma Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Panpharma Main Business Overview
13.5.5 Panpharma Latest Developments
13.6 Rotexmedica GmbH
13.6.1 Rotexmedica GmbH Company Information
13.6.2 Rotexmedica GmbH Unfractionated Heparin Product Portfolios and Specifications
13.6.3 Rotexmedica GmbH Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Rotexmedica GmbH Main Business Overview
13.6.5 Rotexmedica GmbH Latest Developments
13.7 Bharat Serums and Vaccines
13.7.1 Bharat Serums and Vaccines Company Information
13.7.2 Bharat Serums and Vaccines Unfractionated Heparin Product Portfolios and Specifications
13.7.3 Bharat Serums and Vaccines Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Bharat Serums and Vaccines Main Business Overview
13.7.5 Bharat Serums and Vaccines Latest Developments
13.8 Troikaa Pharmaceuticals
13.8.1 Troikaa Pharmaceuticals Company Information
13.8.2 Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolios and Specifications
13.8.3 Troikaa Pharmaceuticals Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Troikaa Pharmaceuticals Main Business Overview
13.8.5 Troikaa Pharmaceuticals Latest Developments
13.9 Wellona Pharma
13.9.1 Wellona Pharma Company Information
13.9.2 Wellona Pharma Unfractionated Heparin Product Portfolios and Specifications
13.9.3 Wellona Pharma Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Wellona Pharma Main Business Overview
13.9.5 Wellona Pharma Latest Developments
13.10 B. Braun
13.10.1 B. Braun Company Information
13.10.2 B. Braun Unfractionated Heparin Product Portfolios and Specifications
13.10.3 B. Braun Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 B. Braun Main Business Overview
13.10.5 B. Braun Latest Developments
13.11 Bioiberica
13.11.1 Bioiberica Company Information
13.11.2 Bioiberica Unfractionated Heparin Product Portfolios and Specifications
13.11.3 Bioiberica Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Bioiberica Main Business Overview
13.11.5 Bioiberica Latest Developments
13.12 Sagent Pharmaceuticals, Inc
13.12.1 Sagent Pharmaceuticals, Inc Company Information
13.12.2 Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolios and Specifications
13.12.3 Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Sagent Pharmaceuticals, Inc Main Business Overview
13.12.5 Sagent Pharmaceuticals, Inc Latest Developments
13.13 Gland Pharma Limited
13.13.1 Gland Pharma Limited Company Information
13.13.2 Gland Pharma Limited Unfractionated Heparin Product Portfolios and Specifications
13.13.3 Gland Pharma Limited Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Gland Pharma Limited Main Business Overview
13.13.5 Gland Pharma Limited Latest Developments
13.14 Stanex
13.14.1 Stanex Company Information
13.14.2 Stanex Unfractionated Heparin Product Portfolios and Specifications
13.14.3 Stanex Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Stanex Main Business Overview
13.14.5 Stanex Latest Developments
13.15 Mylan
13.15.1 Mylan Company Information
13.15.2 Mylan Unfractionated Heparin Product Portfolios and Specifications
13.15.3 Mylan Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Mylan Main Business Overview
13.15.5 Mylan Latest Developments
13.16 Rewine Pharmaceutical
13.16.1 Rewine Pharmaceutical Company Information
13.16.2 Rewine Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications
13.16.3 Rewine Pharmaceutical Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Rewine Pharmaceutical Main Business Overview
13.16.5 Rewine Pharmaceutical Latest Developments
13.17 Jianyou Pharmaceutical
13.17.1 Jianyou Pharmaceutical Company Information
13.17.2 Jianyou Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications
13.17.3 Jianyou Pharmaceutical Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Jianyou Pharmaceutical Main Business Overview
13.17.5 Jianyou Pharmaceutical Latest Developments
13.18 Shenzhen Techdow Pharmaceutical
13.18.1 Shenzhen Techdow Pharmaceutical Company Information
13.18.2 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications
13.18.3 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Shenzhen Techdow Pharmaceutical Main Business Overview
13.18.5 Shenzhen Techdow Pharmaceutical Latest Developments
13.19 Changshan Pharma
13.19.1 Changshan Pharma Company Information
13.19.2 Changshan Pharma Unfractionated Heparin Product Portfolios and Specifications
13.19.3 Changshan Pharma Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Changshan Pharma Main Business Overview
13.19.5 Changshan Pharma Latest Developments
13.20 Dongcheng Pharmaceutical
13.20.1 Dongcheng Pharmaceutical Company Information
13.20.2 Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications
13.20.3 Dongcheng Pharmaceutical Unfractionated Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Dongcheng Pharmaceutical Main Business Overview
13.20.5 Dongcheng Pharmaceutical Latest Developments
14 Research Findings and Conclusion
List Of Tables
List of Tables Table 1. Unfractionated Heparin Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions) Table 2. Unfractionated Heparin Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions) Table 3. Major Players of Heparin Sodium Table 4. Major Players of Heparin Calcium Table 5. Global Unfractionated Heparin Sales by Type (2020-2025) & (K Dose) Table 6. Global Unfractionated Heparin Sales Market Share by Type (2020-2025) Table 7. Global Unfractionated Heparin Revenue by Type (2020-2025) & ($ million) Table 8. Global Unfractionated Heparin Revenue Market Share by Type (2020-2025) Table 9. Global Unfractionated Heparin Sale Price by Type (2020-2025) & (US$/Dose) Table 10. Global Unfractionated Heparin Sale by Application (2020-2025) & (K Dose) Table 11. Global Unfractionated Heparin Sale Market Share by Application (2020-2025) Table 12. Global Unfractionated Heparin Revenue by Application (2020-2025) & ($ million) Table 13. Global Unfractionated Heparin Revenue Market Share by Application (2020-2025) Table 14. Global Unfractionated Heparin Sale Price by Application (2020-2025) & (US$/Dose) Table 15. Global Unfractionated Heparin Sales by Company (2020-2025) & (K Dose) Table 16. Global Unfractionated Heparin Sales Market Share by Company (2020-2025) Table 17. Global Unfractionated Heparin Revenue by Company (2020-2025) & ($ millions) Table 18. Global Unfractionated Heparin Revenue Market Share by Company (2020-2025) Table 19. Global Unfractionated Heparin Sale Price by Company (2020-2025) & (US$/Dose) Table 20. Key Manufacturers Unfractionated Heparin Producing Area Distribution and Sales Area Table 21. Players Unfractionated Heparin Products Offered Table 22. Unfractionated Heparin Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) Table 23. New Products and Potential Entrants Table 24. Market M&A Activity & Strategy Table 25. Global Unfractionated Heparin Sales by Geographic Region (2020-2025) & (K Dose) Table 26. Global Unfractionated Heparin Sales Market Share Geographic Region (2020-2025) Table 27. Global Unfractionated Heparin Revenue by Geographic Region (2020-2025) & ($ millions) Table 28. Global Unfractionated Heparin Revenue Market Share by Geographic Region (2020-2025) Table 29. Global Unfractionated Heparin Sales by Country/Region (2020-2025) & (K Dose) Table 30. Global Unfractionated Heparin Sales Market Share by Country/Region (2020-2025) Table 31. Global Unfractionated Heparin Revenue by Country/Region (2020-2025) & ($ millions) Table 32. Global Unfractionated Heparin Revenue Market Share by Country/Region (2020-2025) Table 33. Americas Unfractionated Heparin Sales by Country (2020-2025) & (K Dose) Table 34. Americas Unfractionated Heparin Sales Market Share by Country (2020-2025) Table 35. Americas Unfractionated Heparin Revenue by Country (2020-2025) & ($ millions) Table 36. Americas Unfractionated Heparin Sales by Type (2020-2025) & (K Dose) Table 37. Americas Unfractionated Heparin Sales by Application (2020-2025) & (K Dose) Table 38. APAC Unfractionated Heparin Sales by Region (2020-2025) & (K Dose) Table 39. APAC Unfractionated Heparin Sales Market Share by Region (2020-2025) Table 40. APAC Unfractionated Heparin Revenue by Region (2020-2025) & ($ millions) Table 41. APAC Unfractionated Heparin Sales by Type (2020-2025) & (K Dose) Table 42. APAC Unfractionated Heparin Sales by Application (2020-2025) & (K Dose) Table 43. Europe Unfractionated Heparin Sales by Country (2020-2025) & (K Dose) Table 44. Europe Unfractionated Heparin Revenue by Country (2020-2025) & ($ millions) Table 45. Europe Unfractionated Heparin Sales by Type (2020-2025) & (K Dose) Table 46. Europe Unfractionated Heparin Sales by Application (2020-2025) & (K Dose) Table 47. Middle East & Africa Unfractionated Heparin Sales by Country (2020-2025) & (K Dose) Table 48. Middle East & Africa Unfractionated Heparin Revenue Market Share by Country (2020-2025) Table 49. Middle East & Africa Unfractionated Heparin Sales by Type (2020-2025) & (K Dose) Table 50. Middle East & Africa Unfractionated Heparin Sales by Application (2020-2025) & (K Dose) Table 51. Key Market Drivers & Growth Opportunities of Unfractionated Heparin Table 52. Key Market Challenges & Risks of Unfractionated Heparin Table 53. Key Industry Trends of Unfractionated Heparin Table 54. Unfractionated Heparin Raw Material Table 55. Key Suppliers of Raw Materials Table 56. Unfractionated Heparin Distributors List Table 57. Unfractionated Heparin Customer List Table 58. Global Unfractionated Heparin Sales Forecast by Region (2026-2031) & (K Dose) Table 59. Global Unfractionated Heparin Revenue Forecast by Region (2026-2031) & ($ millions) Table 60. Americas Unfractionated Heparin Sales Forecast by Country (2026-2031) & (K Dose) Table 61. Americas Unfractionated Heparin Annual Revenue Forecast by Country (2026-2031) & ($ millions) Table 62. APAC Unfractionated Heparin Sales Forecast by Region (2026-2031) & (K Dose) Table 63. APAC Unfractionated Heparin Annual Revenue Forecast by Region (2026-2031) & ($ millions) Table 64. Europe Unfractionated Heparin Sales Forecast by Country (2026-2031) & (K Dose) Table 65. Europe Unfractionated Heparin Revenue Forecast by Country (2026-2031) & ($ millions) Table 66. Middle East & Africa Unfractionated Heparin Sales Forecast by Country (2026-2031) & (K Dose) Table 67. Middle East & Africa Unfractionated Heparin Revenue Forecast by Country (2026-2031) & ($ millions) Table 68. Global Unfractionated Heparin Sales Forecast by Type (2026-2031) & (K Dose) Table 69. Global Unfractionated Heparin Revenue Forecast by Type (2026-2031) & ($ millions) Table 70. Global Unfractionated Heparin Sales Forecast by Application (2026-2031) & (K Dose) Table 71. Global Unfractionated Heparin Revenue Forecast by Application (2026-2031) & ($ millions) Table 72. Sanofi Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 73. Sanofi Unfractionated Heparin Product Portfolios and Specifications Table 74. Sanofi Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 75. Sanofi Main Business Table 76. Sanofi Latest Developments Table 77. Pfizer Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 78. Pfizer Unfractionated Heparin Product Portfolios and Specifications Table 79. Pfizer Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 80. Pfizer Main Business Table 81. Pfizer Latest Developments Table 82. Organon Canada Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 83. Organon Canada Unfractionated Heparin Product Portfolios and Specifications Table 84. Organon Canada Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 85. Organon Canada Main Business Table 86. Organon Canada Latest Developments Table 87. Leo Pharma Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 88. Leo Pharma Unfractionated Heparin Product Portfolios and Specifications Table 89. Leo Pharma Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 90. Leo Pharma Main Business Table 91. Leo Pharma Latest Developments Table 92. Panpharma Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 93. Panpharma Unfractionated Heparin Product Portfolios and Specifications Table 94. Panpharma Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 95. Panpharma Main Business Table 96. Panpharma Latest Developments Table 97. Rotexmedica GmbH Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 98. Rotexmedica GmbH Unfractionated Heparin Product Portfolios and Specifications Table 99. Rotexmedica GmbH Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 100. Rotexmedica GmbH Main Business Table 101. Rotexmedica GmbH Latest Developments Table 102. Bharat Serums and Vaccines Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 103. Bharat Serums and Vaccines Unfractionated Heparin Product Portfolios and Specifications Table 104. Bharat Serums and Vaccines Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 105. Bharat Serums and Vaccines Main Business Table 106. Bharat Serums and Vaccines Latest Developments Table 107. Troikaa Pharmaceuticals Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 108. Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolios and Specifications Table 109. Troikaa Pharmaceuticals Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 110. Troikaa Pharmaceuticals Main Business Table 111. Troikaa Pharmaceuticals Latest Developments Table 112. Wellona Pharma Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 113. Wellona Pharma Unfractionated Heparin Product Portfolios and Specifications Table 114. Wellona Pharma Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 115. Wellona Pharma Main Business Table 116. Wellona Pharma Latest Developments Table 117. B. Braun Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 118. B. Braun Unfractionated Heparin Product Portfolios and Specifications Table 119. B. Braun Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 120. B. Braun Main Business Table 121. B. Braun Latest Developments Table 122. Bioiberica Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 123. Bioiberica Unfractionated Heparin Product Portfolios and Specifications Table 124. Bioiberica Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 125. Bioiberica Main Business Table 126. Bioiberica Latest Developments Table 127. Sagent Pharmaceuticals, Inc Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 128. Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolios and Specifications Table 129. Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 130. Sagent Pharmaceuticals, Inc Main Business Table 131. Sagent Pharmaceuticals, Inc Latest Developments Table 132. Gland Pharma Limited Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 133. Gland Pharma Limited Unfractionated Heparin Product Portfolios and Specifications Table 134. Gland Pharma Limited Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 135. Gland Pharma Limited Main Business Table 136. Gland Pharma Limited Latest Developments Table 137. Stanex Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 138. Stanex Unfractionated Heparin Product Portfolios and Specifications Table 139. Stanex Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 140. Stanex Main Business Table 141. Stanex Latest Developments Table 142. Mylan Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 143. Mylan Unfractionated Heparin Product Portfolios and Specifications Table 144. Mylan Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 145. Mylan Main Business Table 146. Mylan Latest Developments Table 147. Rewine Pharmaceutical Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 148. Rewine Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications Table 149. Rewine Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 150. Rewine Pharmaceutical Main Business Table 151. Rewine Pharmaceutical Latest Developments Table 152. Jianyou Pharmaceutical Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 153. Jianyou Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications Table 154. Jianyou Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 155. Jianyou Pharmaceutical Main Business Table 156. Jianyou Pharmaceutical Latest Developments Table 157. Shenzhen Techdow Pharmaceutical Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 158. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications Table 159. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 160. Shenzhen Techdow Pharmaceutical Main Business Table 161. Shenzhen Techdow Pharmaceutical Latest Developments Table 162. Changshan Pharma Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 163. Changshan Pharma Unfractionated Heparin Product Portfolios and Specifications Table 164. Changshan Pharma Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 165. Changshan Pharma Main Business Table 166. Changshan Pharma Latest Developments Table 167. Dongcheng Pharmaceutical Basic Information, Unfractionated Heparin Manufacturing Base, Sales Area and Its Competitors Table 168. Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolios and Specifications Table 169. Dongcheng Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025) Table 170. Dongcheng Pharmaceutical Main Business Table 171. Dongcheng Pharmaceutical Latest Developments List of Figures Figure 1. Picture of Unfractionated Heparin Figure 2. Unfractionated Heparin Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Unfractionated Heparin Sales Growth Rate 2020-2031 (K Dose) Figure 7. Global Unfractionated Heparin Revenue Growth Rate 2020-2031 ($ millions) Figure 8. Unfractionated Heparin Sales by Geographic Region (2020, 2024 & 2031) & ($ millions) Figure 9. Unfractionated Heparin Sales Market Share by Country/Region (2024) Figure 10. Unfractionated Heparin Sales Market Share by Country/Region (2020, 2024 & 2031) Figure 11. Product Picture of Heparin Sodium Figure 12. Product Picture of Heparin Calcium Figure 13. Global Unfractionated Heparin Sales Market Share by Type in 2025 Figure 14. Global Unfractionated Heparin Revenue Market Share by Type (2020-2025) Figure 15. Unfractionated Heparin Consumed in Deep Vein Thrombosis (DVT) Figure 16. Global Unfractionated Heparin Market: Deep Vein Thrombosis (DVT) (2020-2025) & (K Dose) Figure 17. Unfractionated Heparin Consumed in Pulmonary Embolism (PE) Figure 18. Global Unfractionated Heparin Market: Pulmonary Embolism (PE) (2020-2025) & (K Dose) Figure 19. Unfractionated Heparin Consumed in Myocardial Infarction Figure 20. Global Unfractionated Heparin Market: Myocardial Infarction (2020-2025) & (K Dose) Figure 21. Unfractionated Heparin Consumed in Unstable Angina Figure 22. Global Unfractionated Heparin Market: Unstable Angina (2020-2025) & (K Dose) Figure 23. Unfractionated Heparin Consumed in Atrial Fibrillation-related Clots Figure 24. Global Unfractionated Heparin Market: Atrial Fibrillation-related Clots (2020-2025) & (K Dose) Figure 25. Unfractionated Heparin Consumed in Other Figure 26. Global Unfractionated Heparin Market: Other (2020-2025) & (K Dose) Figure 27. Global Unfractionated Heparin Sale Market Share by Application (2024) Figure 28. Global Unfractionated Heparin Revenue Market Share by Application in 2025 Figure 29. Unfractionated Heparin Sales by Company in 2025 (K Dose) Figure 30. Global Unfractionated Heparin Sales Market Share by Company in 2025 Figure 31. Unfractionated Heparin Revenue by Company in 2025 ($ millions) Figure 32. Global Unfractionated Heparin Revenue Market Share by Company in 2025 Figure 33. Global Unfractionated Heparin Sales Market Share by Geographic Region (2020-2025) Figure 34. Global Unfractionated Heparin Revenue Market Share by Geographic Region in 2025 Figure 35. Americas Unfractionated Heparin Sales 2020-2025 (K Dose) Figure 36. Americas Unfractionated Heparin Revenue 2020-2025 ($ millions) Figure 37. APAC Unfractionated Heparin Sales 2020-2025 (K Dose) Figure 38. APAC Unfractionated Heparin Revenue 2020-2025 ($ millions) Figure 39. Europe Unfractionated Heparin Sales 2020-2025 (K Dose) Figure 40. Europe Unfractionated Heparin Revenue 2020-2025 ($ millions) Figure 41. Middle East & Africa Unfractionated Heparin Sales 2020-2025 (K Dose) Figure 42. Middle East & Africa Unfractionated Heparin Revenue 2020-2025 ($ millions) Figure 43. Americas Unfractionated Heparin Sales Market Share by Country in 2025 Figure 44. Americas Unfractionated Heparin Revenue Market Share by Country (2020-2025) Figure 45. Americas Unfractionated Heparin Sales Market Share by Type (2020-2025) Figure 46. Americas Unfractionated Heparin Sales Market Share by Application (2020-2025) Figure 47. United States Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 48. Canada Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 49. Mexico Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 50. Brazil Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 51. APAC Unfractionated Heparin Sales Market Share by Region in 2025 Figure 52. APAC Unfractionated Heparin Revenue Market Share by Region (2020-2025) Figure 53. APAC Unfractionated Heparin Sales Market Share by Type (2020-2025) Figure 54. APAC Unfractionated Heparin Sales Market Share by Application (2020-2025) Figure 55. China Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 56. Japan Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 57. South Korea Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 58. Southeast Asia Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 59. India Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 60. Australia Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 61. China Taiwan Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 62. Europe Unfractionated Heparin Sales Market Share by Country in 2025 Figure 63. Europe Unfractionated Heparin Revenue Market Share by Country (2020-2025) Figure 64. Europe Unfractionated Heparin Sales Market Share by Type (2020-2025) Figure 65. Europe Unfractionated Heparin Sales Market Share by Application (2020-2025) Figure 66. Germany Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 67. France Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 68. UK Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 69. Italy Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 70. Russia Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 71. Middle East & Africa Unfractionated Heparin Sales Market Share by Country (2020-2025) Figure 72. Middle East & Africa Unfractionated Heparin Sales Market Share by Type (2020-2025) Figure 73. Middle East & Africa Unfractionated Heparin Sales Market Share by Application (2020-2025) Figure 74. Egypt Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 75. South Africa Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 76. Israel Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 77. Turkey Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 78. GCC Countries Unfractionated Heparin Revenue Growth 2020-2025 ($ millions) Figure 79. Manufacturing Cost Structure Analysis of Unfractionated Heparin in 2025 Figure 80. Manufacturing Process Analysis of Unfractionated Heparin Figure 81. Industry Chain Structure of Unfractionated Heparin Figure 82. Channels of Distribution Figure 83. Global Unfractionated Heparin Sales Market Forecast by Region (2026-2031) Figure 84. Global Unfractionated Heparin Revenue Market Share Forecast by Region (2026-2031) Figure 85. Global Unfractionated Heparin Sales Market Share Forecast by Type (2026-2031) Figure 86. Global Unfractionated Heparin Revenue Market Share Forecast by Type (2026-2031) Figure 87. Global Unfractionated Heparin Sales Market Share Forecast by Application (2026-2031) Figure 88. Global Unfractionated Heparin Revenue Market Share Forecast by Application (2026-2031)
Companies Mentioned
Sanofi
Pfizer
Organon Canada
Leo Pharma
Panpharma
Rotexmedica GmbH
Bharat Serums and Vaccines
Troikaa Pharmaceuticals
Wellona Pharma
B. Braun
Bioiberica
Sagent Pharmaceuticals, Inc
Gland Pharma Limited
Stanex
Mylan
Rewine Pharmaceutical
Jianyou Pharmaceutical
Shenzhen Techdow Pharmaceutical
Changshan Pharma
Dongcheng Pharmaceutical
Methodology
LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
Data Sourse
Primary Source
Secondary Source
Players/Suppliers
Journals and Periodicals
Industry Experts
Government Bodies
Distributors/Traders
Annual Reports
Opinion Leaders
Presentations
Front-line Staff
Paid Databases
Marketing Executives
LPI Internal Repository
Data Analysis
Data Synthesis
Data Validation
Information Gathering
Triangulation with Data Models
Collation of Data
Reference Against Proprietary
Estimation of Key Figures
Databases
Analysis of Derived Insights
Corroboration with Industry Experts
Writing And Finishing Report
Qualitative Analysis
Qualitative Analysis
Market drivers
Market size and forecast
Market challenges
Market segmentation
Market trends
Geographical insights
Five forces analysis
Competitive landscape
Have A Question?
Provide comprehensive and accurate analysis and reports according to your exact requirements.
Contact Us
Select A Format
Single User License
USD3660
Multi Users License
USD5490
Corporate Users License
USD7320
Buy Now
Add To Cart
Or More Options：
PDF Download
Sample Request
Custom Request
Jump To Content
Description
Table Of Contents
List Of Tables
Companies Mentioned
Methodology
Have A Question?
Provide comprehensive and accurate analysis and reports according to your exact requirements.
Contact Us
17890 Castleton St. Suite 162 City of Industry, CA 91748 United States
Copyright © 2016-2025 LP Information All Rights Reserved
